In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease

Gut

Volumn 40, Issue 4, 1997, Pages 475-480

  Reimund, J M ^a,b,c   Dumont, S ^b   Muller, C D ^d   Kenney, J S ^d   Kedinger, M ^c   Baumann, R ^a   Poindron, P ^b   Duclos, B ^a,c  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b Dept d'Immunol I   (France)

^c INSERM   (France)

^d Laboratoire de Biophysique   (France)

Author keywords

Cyclic nucleotide phosphodiesterase inhibitors; Inflammatory bowel disease; Inflammatory cytokines; Oxpentifylline

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030927340     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.4.475     Document Type: Article

References (46)

1. Reimund JM, Duclos B, Sapin R, Derlon A, Chamouard P, Baumann R. Systemic tumour necrosis factor in Crohn's disease: relationship to disease activity and circulating acute phase reactants. Eur J Gastroenterol Hepatol 1992; 4: 919-23.
2. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
3. Mazlam MZ, Hodgson HJF. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992; 33: 773-8.
4. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
5. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, Duclos B. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 144-50.
6. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B. Increased production of tumour necrosis factor-alpha, IL-1β and IL-6 by morphologically normal intestinal biopsies in Crohn's disease. Gut 1996; 39: 684-9.
7. Sher ME, D'Angelo AJ, Stein TA, Bailey B, Burns G. Cytokines in Crohn's colitis. Am J Surg 1995; 169: 133-6.
8. Mazlam MZ, Montazeri G, Hodgson HJF. The effects of some anti-inflammatory agents on cytokine release from human monocytes in vitro, Eur J Gastroenterol Hepatol 1993; 5: 51 5-20.
9. Mitsuyama K, Sasaki E, Toyonaga A, Ikeda H, Tsuruta O, Irie A, et al. Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 1991; 50: 104-11.
10. Mitsuyama K, Toyonaga A, Sasaki E, Watanabe K, Tateishi H, Nishiyama T, et al. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 1994; 96: 432-6.
11. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat GNJ, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4.
12. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
13. Targan S, Rutgeerts P, Hanauer SB, Van Deventer HJS, Mayer L, Present DH, et al. A multicenter trial of antitumor necrosis factor (TNF) antibody (cA2) for treatment of patients with active Crohn's disease [abstract]. Gastroenterology 1996; 110: A1026.
14. Henderson B, Blake S. Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci 1992; 13: 145-52.
15. Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effects of pentoxifylline on the phagocytic activity, cAMP levels, and Superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyte Biol 1986; 40: 747-57.
16. Tannenbaum CS, Hamilton TA. Lipopolysaccharide-induced gene expression in murine peritoneal macro-phages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 1989; 142: 1274-80.
17. Lennard-Jones JE. Definition and diagnosis in regional enteritis. Skandia International Symposium Nordiska. Stockholm: SISN, 1971: 105-116.
18. Van Hees PAM, Van Elteren PH, Van Lier HJJ, Van Tongeren JHM. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279-86.
19. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955; ii: 1041-8.
20. Bøyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Lab Invest 1968; 21: 77 89.
21. Wardle TD, Hall L, Turnberg LA. Use of coeulture of colonie mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut 1992; 33: 1644-51.
22. Kenney JS, Masada MP, Eugui EM, Delustro BM, Mulkins MA, Allison AC. Monoclonal antibodies to human recombinant interleukin 1 (IL1) β: quantification of IL1β and inhibition of biological activity. J Immunol 1987; 138: 4236-42.
23. Novak KJ, Rothenberg EV. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci USA 1990; 87: 9353-7.
24. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in signaling pathway. J Exp Med 1990; 172: 391 4.
25. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103: 65-71.
26. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grünwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells. Immunology 1994; 83: 262-7.
27. Bienvenu J, Doche C, Gutowski M-C, Lenoble M, Lepape A, Perdrix J-P. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995; 25 (suppl 2): S80-4.
28. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2 and interferon gamma secreting cells in normal and diseased human intestinal mucosa. Immunology 1993; 78: 127 31.
29. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993; 23: 1745-51.
30. Thanhaüser A, Roiling N, Böhle A, Toellner K-M, Duchrow M, Scheel D, et al. Pentoxifylline: a potent inhibitor of IL-2 and IFN-γ biosynthesis and BCG-induced cytotoxicity. Immunology 1993; 80: 151-6.
31. 2 inhibits production of Th1 lymphokines but not of Th2 Iymphokines. J Immunol 1991; 146: 108-13.
32. Waage A, Sorensen M, Stordal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet 1990; 335: 543.
33. Schandené L, Vandenbussche P, Crusiaux A, Alègre ML, Abramowicz D, Dupont E, et al. Differential effects of pentoxifylline on the production of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992; 76: 30-4.
34. Beutler B, Kruys V. Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. J Cardiovasc Pharmacol 1995; 25 (suppl 2): S1-8.
35. Hakim J. Pharmacologic control of intracellular signaling pathways: from research to therapy. J Cardiovasc Pharmacol 1995; 25 (suppl 2): S106-13.
36. Endres S, Fülle H-J, Sinha B, Stoll D, Dinarello CA, Gerzer R, et al. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1βby human mononuclear cells. Immunology 1991; 72: 56-60.
37. Stricter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, et al. Cellular and molecular regulation of the tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-6.
38. 2B cell stimulatory' factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem 1988; 263: 6177-82.
39. Ollivier V, Ternisien C, Vu T, Hakim J, De Prost D. Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes. FEBS Lett 1993; 322: 231-4.
40. Ramani M, Khechai F, Ollivier V, Ternisien C, Bridey F, Hakim D, et al. Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes. FEBS Lett 1994; 356: 86-8.
41. De Fraissinette A, Berman B, Duncan MR, Lefevre L. Effects of pentoxifylline on interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) induction of intercellular adhesion molecule-1 (ICAM-1) expression on human keratinocytes and Langerhans cells. Eur J Dermatol 1992; 2: 266-72.
42. Peterson TC, Isbrucker RA, Hooper ML. In vitro effects of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists, Immunopharmacology 1994; 28: 259-70.
43. Reimund JM, Muller Ch, Dumont S, Allison AC, Baumann R, Poindron Ph, et al. Comparaison de l'effet in vitro de certains anti-oxydants et de la pentoxifylline (POF) sur la sécrétion de cytokines au cours des maladies inflammatoires chroniques de l'intestin (MICI) [abstract], Gastrocnterol Clin Biol 1995; 19: A36.
44. Kam I, Casini-Raggi V, Cominelli F. Pentoxifylline: a novel treatment for ulcerative colitis [abstract]. Gastroenterologey 1995; 108: A845.
45. Bauditz J, Rückert Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease, Lancet 1999; 345: 1445.
46. DeVault GA, Kohan DE, Nelson EW, Holman JM. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 1994; 57: 532-40.